MRNA

#561
Moderna, Inc. - Common Stock
47.1 9 USD
-0.80%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
47.19
47.19
Jahresspanne
22.29
59.55
Tagesänderung
-0.80%
Monatliche Änderung
+2.12%
6 month change
+88.38%
Jahresänderung
+78.75%
Vorheriger Schlusskurs
47.5 7
Open
47.1 9
Tief
47.1 9
High
47.1 9
Volumen
365
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 18.72 B
  • Employee 4 700
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry Biotechnologie
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-4.06
Preis-Umsatz-Verhältnis
5.9

Moderna, Inc. - Common Stock

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

Nachrichten